Exhibit 99.1 Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results – 14% year-over-year revenue increase from combined key growth drivers: Xywav , Epidiolex and Rylaze – – 2024 total revenue guidance affirmed at $4.0 to $4.1 billion – – Zanidatamab 2L BTC PDUFA date of November 29, 2024 – – Plan to submit sNDA for Zepzelca in 1L ES-SCLC in 1H25 – ® ® ® ® DUBLIN, November 6, 2024 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and updat ...